David S. Siegel, MD, PhD

David S. Siegel, MD, is the chief of the Division of Multiple Myeloma at the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey.

Articles

Dr Siegel on the Evaluation of Mezigdomide for R/R Myeloma

April 30th 2025

David S. Siegel, MD, explains the rationale for assessing mezigdomide—a novel thalidomide derivative—in relapsed/refractory multiple myeloma.

Dr Siegel on the Need for Durable Remissions in Patients With Multiple Myeloma

July 23rd 2024

David Samuel Dicapua Siegel, MD, discusses unmet needs and current challenges within multiple myeloma.

Dr Siegel on Real-World Outcomes With Tandem Transplant in Newly Diagnosed Myeloma

June 25th 2024

David Samuel Dicapua Siegel, MD, discusses real-world outcomes with tandem transplantation in newly diagnosed multiple myeloma.

Dr Siegel on the Rationale for Investigating KID in Multiple Myeloma

February 8th 2024

David Samuel Dicapua Siegel, MD, discusses a trial of carfilzomib, iberdomide, and dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.

Inside the Clinic: JTCC Experts Highlight Key Takeaways from ASH 2021

March 7th 2022

David Siegel, MD, PhD, Noa Biran, MD, and David H. Vesole, MD, PhD, discuss key takeaways from ASH 2021.

Inside the Clinic: JTCC Experts Highlight Pivotal Ongoing Trials in Multiple Myeloma

March 7th 2022

David Siegel, MD, PhD, Noa Biran, MD, and David H. Vesole, MD, PhD, discuss ongoing clinical trials in multiple myeloma.

Dr. Siegel on the Cost of Cancer Care

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on the escalating costs associated with cancer car

Dr. Siegel Discusses Ongoing Myeloma Clinical Trials

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, discusses ongoing myeloma clinical trials in the spring of 2011.

Dr. Siegel Discusses Accelerated Drug Approval

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, explains his thoughts on accelerated drug approvals.

Dr. Siegel on Biomarkers and Molecular Analysis

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on biomarkers and molecular analysis.

Dr. Siegel on the PX-171-003-A1 Carfilzomib Study

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, explains a clinical trial that looked at the newly approved agent carfilzomib.

Dr. Siegel on His Presentation at the 2010 ASH Meeting

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on his presentation at the 2010 American Society of Hematology (ASH) conference.

Dr. Siegel on the Practice Changes the Past 10 Years

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on how his practice has changed over the past 10 years.

Dr. Siegel on Drugs Discussed at the 2010 ASH Meeting

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on new drugs discussed at the 2010 American Society of Hematology Conference.

Dr. Siegel on the Carfilzomib FDA Approval Process

March 14th 2011

Dr. David Siegel from John Theurer Cancer Center on the Carfilzomib FDA Approval Process

Dr. Siegel on the Importance of Bisphosphonates

March 14th 2011

David S. Siegel, MD, PhD, chief, Multiple Myeloma at John Theurer Cancer Center, on the importance of bisphosphonates

Dr. Siegel Discusses the New John Theurer Cancer Center

March 14th 2011

David S. Siegel, MD, PhD, chief, Multiple Myeloma at the John Theurer Cancer Center (JTCC), discusses the new JTCC stand alone cancer center.